Proteomics and genomics of urinary bladder cancer

Proteomics - Clinical Applications

Volumn 2, Issue 9, 2008, Pages 1194-1207

  Mohammed, Sulma I ^a,b,c   Rahman, Munazzah ^a  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Biomarkers; Bladder; Genomics; Urothelial carcinoma

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; CALRETICULIN; CATECHOL METHYLTRANSFERASE; CD34 ANTIGEN; CELL ADHESION MOLECULE; CELL CYCLE PROTEIN; CYCLOOXYGENASE 2; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRIN DEGRADATION PRODUCT; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GAMMA SYNUCLEIN; HEAT SHOCK PROTEIN 27; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MYC PROTEIN; NUCLEAR MATRIX PROTEIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN S 100; RETINOBLASTOMA PROTEIN; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

BLADDER CANCER; CHROMOSOME 13P; CHROMOSOME 17P; CHROMOSOME 9P; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN GLYCOSYLATION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 53549093030     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780089     Document Type: Review

References (153)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y. et al., Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
2. Brown, M. L., Riley, G. F., Schussler, N., Etzioni, R., Estimating health care costs related to cancer treatment from SEER-Medicare data. Med. Care 2002, 40, IV-104-117.
3. Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y. et al., Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 2004, 50, 857-866.
4. Greene, F. L., Page, D., Fleming, I., Fritz, A. et al., AJCC cancer staging handbook, Springer-Verlag, New York 2002, (6), pp.367-74.
5. Sanchez-Carbayo, M., Recent advances in bladder cancer diagnostics. Clin. Biochem. 2004, 37, 562-571.
6. Henry, N. L., Macvicar, G., Hussain, M., Management of patients with muscle-invasive and metestatic bladder cancer. Oncology (Williston Park) 2005, 19, 1333-1342; discussion 42, 47, 50 passim.
7. Karakiewicz, P. I., Benayoun, S., Zippe, C., Ludecke, G. et al., Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006, 97, 997-1001.
8. Mitropoulos, D., Kiroudi-Voulgari, A., Nikolopoulos, P., Manousakas, T. et al., Accuracy of cystoscopy in predicting histologic features of bladder lesions. J. Endourol. 2006, 19, 861-864.
9. Messing, E. M., Madeb, R., Young, T., Gilchrist, K. W. et al., Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006, 107, 2173-2179.
10. Cai, T., Bartoletti, R., Messing, E. M., Madeb, R. et al., Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2007, 109, 1923-1924; author reply 4.
11. Sheng, K. H., Yao, Y. C., Chuang, S. S., Wu, H. et al., Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 2006, 6, 1058-1065.
12. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K. et al., Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
13. Srinivas, P. R., Srivastava, S., Hanash, S., Wright, G. L., Jr., Proteomics in early detection of cancer. Clin. Chem. 2001, 47, 1901-1911.
14. Celis, J. E., Ostergaard, M., Rasmussen, H. H., Gromov, P. et al., A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 1999, 20, 300-309.
15. Adam, B. L., Vlahou, A., Semmes, O. J., Wright, G. L., Jr., Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001, 1, 1264-1270.
16. Grossman, H. B., Messing, E., Soloway, M., Tomera, K. et al., Detection of bladder cancer using a point-of-care proteomic assay. Jama 2005, 293, 810-816.
17. Attallah, A. M., Sakr, H. A., Ismail, H., Abdel-Hady El, S. K. et al., An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU Int. 2005, 96, 334-339.
18. Getzenberg, R. H., Konety, B. R., Oeler, T. A., Quigley, M. M. et al., Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996, 56, 1690-1694.
19. Konety, B. R., Nguyen, T. S., Dhir, R., Day, R. S. et al., Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin. Cancer Res. 2000, 6, 2618-2625.
20. Konety, B. R., Nguyen, T. S., Brenes, G., Sholder, A. et al., Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 2000, 164, 634-639.
21. Myers-Irvin, J. M., Landsittel, D., Getzenberg, R. H., Use of the novel marker BLCA-1 for the detection of bladder cancer. J. Urol. 2005, 174, 64-68.
22. Ahmad, M., Attoub, S., Singh, M. N., Martin, F. L. et al., Gamma-synuclein and the progression of cancer. FASEB J. 2007, 21, 3419-3430.
23. Iwaki, H., Kageyama, S., Isono, T., Wakabayashi, Y. et al., Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004, 95, 955-961.
24. Irmak, S., Tilki, D., Heukeshoven, J., Oliveira-Ferrer, L. et al., Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5, 4296-4304.
25. Kreunin, P., Zhao, J., Rosser, C., Urquidi, V. et al., Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 2007, 6, 2631-2639.
26. Lebret, T., Watson, R. W., Fitzpatrick, J. M., Heat shock proteins: their role in urological tumors. J. Urol. 2003, 169, 338-346.
27. Gromova, I., Gromov, P., Wolf, H., Celis, J. E., Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. Int. J. Oncol. 1998, 13, 379-383.
28. Ohlsson, G., Moreira, J. M., Gromov, P., Sauter, G. et al., Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol. Cell. Proteomics 2005, 4, 570-581.
29. Celis, J. E., Ostergaard, M., Basse, B., Celis, A. et al., Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 1996, 56, 4782-4790.
30. Mueller, J., Von Eggeling, F., Driesch, D., Schubert, J. et al., ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol. 2005, 47, 885-893; discussion 93-94.
31. Liu, W., Guan, M., Wu, D., Zhang, Y. et al., Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol. 2005, 47, 456-462.
32. Zhang, Y, F., Wu, D. L., Guan, M., Liu, W. W. et al., Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 2004, 37, 772-779.
33. Tai, H. L., Lin, T. S., Huang, H. H., Lin, T. Y. et al., Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol. Rep. 2007, 17, 305-311.
34. Gromov, P. S., Ostergaard, M., Gromova, I., Celis, J. E., Human proteomic databases: a powerful resource for functional genomics in health and disease. Prog. Biophys. Mol. Biol. 2002, 80, 3-22.
35. Simoneau, M., Aboulkassim, T. O., Larue, H., Rousseau, F. et al., Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 1999, 18, 157-163.
36. Van Tilborg, A. A., Groenfeld, L. E., Van Der Kwast, T. H., Zwarthoff, E. C., Evidence for two candidate tumor suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumor cell lines. Br. J. Cancer 1999, 80, 489-494.
37. Kimura, F., Florl, A. R., Selfert, H. H., Louhelainen, J. et al., Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br. J. Cancer 2001, 85, 1887-1893.
38. Louhelainen, J., Wijkstrom, H., Hemminki, K., Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int. J. Cancer 2000, 87, 522-527.
39. Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Li, W, et al., Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol. 2003, 163, 505-516.
40. Veltman, J. A., Fridlyand, J., Pejavar, S., Olahen, A. B. et al., Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003, 63, 2872-2880.
41. Mitra, A. P., Datar, R. H., Cote, R. J., Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 2006, 24, 5552-5564.
42. Schmitz-Drager, B. J., Schulz, W. A., Jurgens, B., Gerharz, C. D. et al., c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urol. Res. 1997, 25 Suppl 1, S45-S49.
43. Schulz, W. A., Jankevicius, F., Gerharz, C. D., Kushima, M. et al., Predictive value of molecular alterations for the prognosis of urothelial carcinoma. Cancer Detect. Prev. 1998, 22, 422-429.
44. Coogan, C. L., Estrada, C. R., Kapur, S., Bloom, K. J., HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004, 63, 786-790.
45. Korkolopoulou, P., Christodoulou, P., Kapralos, P., Exarchakos, M. et al., The role of p53, MDM2 and c-erb B-2 onco-proteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract. 1997, 193, 767-775.
46. Langner, C., Gross, C., Rehak, P., Ratschek, M. et al., HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma; systematic analysis applying tissue microarray technique. Urology 2005, 65, 176-180.
47. Tuna, B., Yorukoglu, K., Tuzel, E., Guray, M. et al., Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol. Res. Pract. 2003, 199, 323-328.
48. Schmitz-Droger, B. J., Kushima, M., Goebell, P., Jax, T. W. et al., p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol. 1997, 32, 487-493.
49. Pflster, C., Moore, L., Allard, P., Larue, H. et al., Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res. 1999, 5, 4079-4084.
50. Shiina, H., Igawa, M., Shigeno, K., Yamasaki, Y. et al., Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptopis. Oncology 1999, 56, 239-247.
51. Uchida, T., Minei, S., Gao, J. P., Wang, C. et al., Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol. Rep. 2002, 9, 253-259.
52. Nakopoulou, L., Vourlakou, C., Zervas, A., Tzonou, A. et al., The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum. Pathol. 1998, 29, 146-154.
53. Vollmer, R. T., Humphrey, P. A., Swanson, P. E., Wick, M. R. et al., Invasion of the bladder by transitional cell carcinoma; its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998, 82, 715-723.
54. Ong, F., Moonen, L. M., Gallee, M. P., Ten Bosch, C. et al., Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother. Oncol. 2001, 61, 169-175.
55. Stavropoulos, N. E., Filiadis, I., Ioachim, E., Hastazeris, K. et al., Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer, Anticancer Res. 2002, 22, 3759-3764.
56. Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P. et al., Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 1998, 58, 1090-1094.
57. Chatterjee, S. J., Deter, R., Youssefzadeh, D., George, B. et al., Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 2004, 22, 1007-1013.
58. Grossman, H. B., Liebert, M., Antelo, M., Dinney, C. P. et al., p53 and RB expression predict progression in T1 bladder cancer. Clin. Cancer Res. 1998, 4, 829-834.
59. Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J. et al., p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 2004, 22, 1014-1024.
60. Burkhard, F. C., Markwalder, R., Thalmann, G. N., Studer, U. E., Immunohistochemical determination of p53 overexpression. An easy and readily available method to identify progression in superficial bladder cancer? Urol. Res. 1997, 25 Suppl 1, S31-S35.
61. Casetta, G., Gontero, P., Russo, R., Pacchioni, D. et al., p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur. Urol. 1997, 32, 228-236.
62. Rabbani, F., Cordon-Cardo, C., Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol. Clin. North Am. 2000, 27, 83-102, ix.
63. Hafner, C., Knuechel, R., Zanardo, L., Dietmaier, W. et al., Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 2001, 20, 4910-4915.
64. Sanchez-Carbayo, M., Socci, N. D., Charytonowicz, E., Lu, M. et al., Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002, 62, 6973-6980.
65. Paterson, R. F., Ulbright, T. M., Maclennan, G. T., Zhang, S. et al., Molecular genetic alterations in the laser-capture-micro-dissected stroma adjacent to bladder carcinoma. Cancer 2003, 98, 1830-1836.
66. Lorenzo Romero, J. G., Salinas Sanchez, A. S., Gimenez Bachs, J. M., Sanchez Sanchez, F. et al., p53 Gene mutations in superficial bladder cancer. Urol. Int. 2004, 73, 212-218.
67. Chatterjee, S. J., George, B., Goebell, P. J., Alavi-Tafreshi, M. et al., Hyperphosphorylation of pRb: a mechanism for RB tumor suppressor pathway inactivation in bladder cancer. J. Pathol. 2004, 203, 762-770.
68. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J. et al., Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst. 1998, 90, 1072-1079.
69. Kamai, T., Takagi, K., Asami, H., Ito, Y. et al., Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br. J. Cancer 2001, 84, 1242-1251.
70. Shariat, S. F., Ashfaq, R., Sagalowsky, A. I., Lotan, Y., Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 2007, 177, 481-487; discussion 7.
71. Tut, V. M., Braithwaite, K. L., Angus, B., Neal, D. E. et al., Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br. J. Cancer 2001, 84, 270-275.
72. Wang, L., Habuchi, T., Takahashi, T., Mitsumori, K. et al., Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002, 23, 257-264.
73. Lee, C. C., Yamamoto, S., Morlmura, K., Wanibuchi, H. et al., Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997, 79, 780-789.
74. Suwa, Y., Takano, Y., Iki, M., Takeda, M. et al., Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder. J. Urol. 1998, 160, 897-900.
75. Abdel-Fattah, R., Challen, C., Griffiths, T. R., Robinson, M. C. et al., Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br. J. Cancer 1998, 77, 2230-.
76. Dahse, R., Utting, M., Werner, W., Schubert, J. et al., Prognostic significance of mutations in the p53 gene in superficial bladder cancer. Oncol. Rep. 2000, 7, 931-936.
77. Lorenzo-Romero, J. G., Salinas-Sanchez, A. S., Gimenez-Bachs, J. M., Sanchez-Sanchez, F. et al., Prognostic implications of p53 gene mutations in bladder tumors. J. Urol. 2003, 169, 492-499.
78. Moonen, P. M., Van Balkan-Ory, B., Kiemeney, L. A., Schalken, J. A. et al., Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J. Urol. 2007, 177, 80-83.
79. Prescott, J. L., Montie, J., Pugh, T. W., Mchugh, T. et al., Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer 2001, 91, 2127-2135.
80. Van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J. et al., The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001, 61, 1265-1268.
81. Mhawech-Fauceglia, P., Cheney, R. T., Fischer, G., Beck, A. et al., FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur. J. Surg. Oncol. 2006, 32, 231-237.
82. Gravas, S., Bosinakou I., Kehayas, P., Giannopoulos, A., Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol. Int. 2004, 73, 173-177.
83. Gomez-Roman, J. J., Saenz, P., Molina, M., Cuevas Gonzalez, J. et al., Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin, Cancer Res. 2005, 11, 459-465.
84. Riegar-Christ, K. M., Mourtzinos, A., Lee, P. J., Zagha, R. M. et al., Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003, 98, 737-744.
85. Van Oers, J. M., Lurkin, I., Van Exsel, A. J., Nijsen, Y. et al., A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 2005, 11, 7743-7748.
86. Chow, N. H., Liu, H. S., Chan, S. H., Cheng, H. L. et al., Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res. 1999, 19, 4593-4597.
87. Jeon, S. H., Lee, S. J., Chang, S. G., Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol. Rep. 2001, 8, 1265-1267.
88. Sun, Y., He, D. L., Ma, Q., Wan, X. Y. et al., Comparison of seven screening methods in the diagnosis of bladder cancer. Chin. Med. J (Engl) 2006, 119, 1763-1771.
89. Canoglu, A., Gogus, C., Beduk, Y., Orhan, D. et al., Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int. Urol. Nephrol. 2004, 36, 401-405.
90. Grossman, H. B., Tangen, C. M., Cordon-Cardo, C., Cote, R. et al., Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol. Rep. 2006, 16, 807-810.
91. Margulis, V., Shariat, S. F., Ashfaq, R., Thompson, M. et al., Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J. Urol. 2007, 177, 1163-1168.
92. Hilmy, M., Campbell, R., Bartlett, J. M., Mcnicol, A. M. et al., The relationship between the systemic inflammatory response, tumor proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 2006, 95, 1234-1238.
93. Sun, W., Herrera, G. A., E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum. Pathol. 2002, 33, 996-1000.
94. Fromont, G., Roupret, M., Amira, N., Sibony, M. et al., Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur. Urol. 2005, 48, 764-770.
95. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K. et al., Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001, 61, 8659-8663.
96. Nakanishi, K., Kawai, T., Kumaki, F., Hiroi, S. et al., Survivin expression in atypical adenomatous hyperplasia of the lung. Am. J. Clin. Pathol. 2003, 120, 712-719.
97. Smith, S. D., Wheeler, M. A., Plescia, J., Colberg, J. W. et al., Urine detection of survivin and diagnosis of bladder cancer. Jama 2001, 285, 324-328.
98. Shariat, S. F., Casella, R., Khoddami, S. M., Hernandez, G. et al., Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J. Urol. 2004, 171, 626-630.
99. Weikert, S., Christoph, F., Schrader, M., Krause, H. et al., Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int. J. Cancer 2005, 116, 100-104.
100. Moussa, O., Abol-Enein, H., Bissada, N. K., Keane, T. et al., Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J. Urol. 2006, 175, 2312-2316.
101. Kenney, D. M., Geschwindt, R. D., Kary, M. R., Linic, J. M. et al., Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumor Biol. 2007, 28, 57-62.
102. Schultz, I. J., De Kok, J. B., Witjes, J. A., Babjuk, M. et al., Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence. Anticancer Res. 2007, 27, 1051-1058.
103. Schultz, I. J., Wester, K., Straatman, H., Kiemeney, L. A. et al., Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur. Urol. 2007, 51, 416-422; discussion 22-23.
104. Staack, A., Badendieck, S., Schnorr, D., Loening, S. A. et al., Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 2006, 6, 19.
105. Frohlich, C., Albrechtsen, R., Dyrskjot, L., Rudkjaer, L. et al., Molecular profiling of ADAM12 in human bladder cancer. Clin. Cancer Res. 2006, 12, 7359-7368.
106. Higgins, J. P., Kaygusuz, G., Wang, L, Montgomery, K. et al., Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am. J. Surg. Pathol. 2007, 31, 673-680.
107. Brunner, A., Ensinger, C., Christiansen, M., Heiss, S. et al., Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch. 2007, 450, 659-664.
108. Mian, C., Lodde, M., Haitel, A., Egarter Vigl, E. et al., Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000, 56, 228-231.
109. Babjuk, M., Kostirova, M., Mudra, K., Pecher, S. et al., Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur. Urol. 2002, 41, 34-39.
110. Christoph, F., Muller, M., Schostak, M., Soong, R. et al., Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 2004, 64, 157-161.
111. Klein, A., Zemer, R., Buchumensky, V., Klaper, R. et al., Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 1998, 82, 349-354.
112. Rotem, D., Cassel, A., Lindenfeld, N., Mecz, Y. et al., Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur. Urol. 2000, 37, 601-604.
113. Buchumensky, V., Klein, A., Zemer, R., Kessler, O. J. et al., Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J. Urol. 1998, 160, 1971-1974.
114. Inoue, T., Nakanishi, H., Inada, K., Hioki, T. et al., Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J. Urol. 2001, 166, 2134-2141.
115. Melissourgos, N. D., Kastrinakis, N. G., Skolarikos, A., Pappa, M. et al., Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 2005, 66, 536-541.
116. Konety, B. R., Getzenberg, R. H., Urine based markers of urological malignancy. J. Urol. 2001, 165, 600-611.
117. Dey, P., Urinary markers of bladder carcinoma. Clin. Chim. Acta 2004, 340, 57-65.
118. Tsihlias, J., Grossman, H. B., The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol. Clin. North Am. 2000, 27, 39-46.
119. Johnston, B., Morales, A., Emerson, L., Lundie, M., Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol. 1997, 158, 2098-2101.
120. Eissa, S., Swellam, M., Sadek, M., Mourad, M. S. et al., Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J. Urol. 2002, 168, 465-469.
121. Gilbert, S. M., Veltri, R. W., Sawczuk, A., Shabsigh, A. et al., Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology 2003, 61, 539-543.
122. Sawczuk, I. S., Pickens, C. L., Vasa, U. R., Ralph, D. A. et al., DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol. Oncol. 2002, 7, 185-190.
123. Dyrskjot, L., Thykjaer, T., Kruhoffer, M., Jensen, J. L. et al., Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 2003, 33, 90-96.
124. Santos, L., Amaro, T., Costa, C., Pereira, S. et al., Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int. J. Cancer 2003, 105, 267-272.
125. Quintero, A., Alvarez-Kindelan, J., Luque, R. J., Gonzalez-Campora, R. et al., Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J. Clin. Pathol. 2006, 59, 83-88.
126. Korkolopoulou, P., Christodoulou, P., Konstantinidou, A. E., Thomas-Tsagli, E. et al., Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum. Pathol. 2000, 31, 751-760.
127. Cheng, H. L., Chow, N. H., Tzai, T. S., Tong, Y. C. et al., Prognostic significance of proliferating cell nuclear antigen expression in transitional cell carcinoma of the upper urinary tract. Anticancer Res. 1997, 17, 2789-2793.
128. Weikert, S., Krause, H., Wolff, I., Christoph, F. et al., Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int. J. Cancer 2005, 117, 274-280.
129. Sanchini, M. A., Gunelli, R., Nanni, O., Bravaccini, S., et al., Relevance of urine telomerase in the diagnosis of bladder cancer. Jama 2005, 294, 2052-2056.
130. Bialkowska-Hobrzanska, H., Bowles, L., Bukala, B., Joseph, M. G. et al., Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma. Mol. Diagn. 2000, 5, 267-277.
131. Landman, J., Chang, Y., Kavaler, E., Droller, M. J. et al., Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998, 52, 398-402.
132. Halling, K. C., King, W., Sokolova, I. A., Karnes, R. J. et al., A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol. 2002, 167, 2001-2006.
133. Lokeshwar, V. B., Obek, C., Pham, H. T., Wei, D. et al., Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J. Urol. 2000, 163, 348-356.
134. Papanicolaou, G. N., Marshall, V. F., Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945, 101, 519-520.
135. Abd El Gawad, I. A., Moussa, H. S., Nasr, M. I., El Gemae, E. H. et al., Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J. Egypt. Natl. Cancer Inst. 2005, 17, 193-202.
136. Garbar, C., Mascaux, C., Wespes, E., Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses. Cytopathology 2007, 18, 79-83.
137. Planz, B., Jochims, E., Deix, T., Caspers, H. P. et al., The role of urinary cytology for detection of bladder cancer. Eur. J. Surg. Oncol. 2005, 31, 304-308.
138. Bastacky, S., Ibrahim, S., Wilczynski, S. P., Murphy, W. M., The accuracy of urinary cytology in daily practice. Cancer 1999, 87, 118-128.
139. Toma, M. I., Friedrich, M. G., Hautmann, S. H., Jakel, K. T. et al., Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J. Urol. 2004, 22, 145-149.
140. Moonen, P. M., Merkx, G. F., Peelen, P., Karthaus, H. F. et al., UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 2007, 51, 1275-1280; discussion 80.
141. Leyh, H., Marberger, M., Conort, P., Sternberg, C. et al., Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur. Urol. 1999, 35, 52-56.
142. Poulakis, V., Witzsch, U., De Vries, R., Altmannsberger, H. M. et al., A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int. 2001, 88, 692-701.
143. Serretta, V., Pomara, G., Rizzo, I., Esposito, E., Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur. Urol. 2000, 38, 419-425.
144. Mian, C., Pycha, A., Wiener, H., Haitel, A. et al., Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J. Urol. 1999, 161, 1486-1489.
145. Tetu, B., Tiguert, R., Harel, F., Fradet, Y., ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod. Pathol. 2005, 18, 83-89.
146. Nielsen, M. E., Schaeffer, E. M., Veltri, R. W., Schoenberg, M. P. et al., Urinary markers in the detection of bladder cancer: what's new? Curr. Opin. Urol. 2006, 16, 350-355.
147. Mian, C., Lodde, M., Comploj, E., Palermo, S. et al., The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res. 2005, 25, 3641-3644.
148. Kumar, A., Kumar, R., Gupta, N. P., Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn. J. Clin. Oncol. 2006, 36, 172-175.
149. Lekili, M., Sener, E., Demir, M. A., Temeltas, G. et al., Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. Urol. Res. 2004, 32, 124-128.
150. Sarosdy, M. F., Schellhammer, P., Bokinsky, G., Kahn, P. et al., Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 2002, 168, 1950-1954.
151. Varella-Garcia, M., Akduman, B., Sunpaweravong, P., Di Maria, M. V. et al., The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol. Oncol. 2004, 22, 16-19.
152. Bassi, P., De Marco, V., De Lisa, A., Mancini, M. et al., Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol. Int. 2005, 75, 193-200.
153. Laudadio, J., Keane, T. E., Reeves, H. M., Savage, S. J. et al., Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005, 96, 1280-1285.